VIR Vir Biotechnology-17.8%Stock move

Vir Biotechnology Stock Falls 18% the Day After Filing for Share Sale

The preliminary prospectus was filed after the close Thursday and left the offering price and share count blank.

science research, work and people concept - international team of happy scientists with microscopes working in laboratory
Photo: Ground Picture/Shutterstock.com

Key points

  • Vir Biotechnology fell 17.8% Friday, closing at $9.96 from $12.12, the day after filing a prospectus for a common stock offering
  • The preliminary filing left the offering price and share count blank
  • Cash and investments together totaled $454.6 million as of Sept. 30
  • Q3 net loss was $96.3 million, narrower than $163.1 million a year earlier

Vir Biotechnology (Nasdaq: VIR) shares fell 17.8% on Friday, Nov. 13, 2026, closing at $9.96 from a previous close of $12.12. The S&P 500 ETF (SPY) moved -0.36% that session, and trading volume ran about 10.7 times its typical level. The drop came the session after the company filed a 424B5 prospectus supplement for a public offering of its common stock, accepted at 4:16 p.m. ET on Thursday, Nov. 12. The company did not state a reason for the decline in the filing.

Offering terms left blank

The preliminary document lists Leerink Partners, Morgan Stanley, Evercore ISI and Raymond James as underwriters. The public offering price and the number of shares offered were blank in the version reviewed. The company said it intends to use net proceeds, together with existing cash and investments, to fund pre-commercial activities for its chronic hepatitis delta (CHD) program, investments in its TCE oncology platform and general corporate purposes. The underwriters also received a 30-day option to buy additional shares.

Cash against recent losses

As of Sept. 30, the company reported cash and equivalents of $218.9 million and short-term investments of $235.8 million, or $454.6 million in cash and investments together. Its net loss for the quarter ended Sept. 30 was $96.3 million, narrower than the $163.1 million loss a year earlier.

Trial results cited in the filing

The prospectus recounts Phase 3 ECLIPSE 1 results presented in November, which met the primary and key secondary endpoints. The primary endpoint showed a 44% response rate for undetectable virus plus ALT normalization at Week 48, compared with 0% in the delayed treatment group. The company said ECLIPSE 2 and ECLIPSE 3 topline data are expected in the first quarter of 2027.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

Other stock movers this week

VIR page →

Filings, figures and price history are on the Vir Biotechnology page.